Key Takeaways:
Citigroup reiterated its “Buy” rating for Fosun International Ltd. (00656.HK) following a strategy meeting, maintaining a price target of HK$5.6 after the conglomerate signaled that recent asset impairments have been fully absorbed.
The bank said in a May 21 research report that one-time, non-cash writedowns taken in fiscal 2025 are digested and do not involve any breach of debt covenants. Citi noted that Fosun’s health and insurance businesses show stable performance, while its “Happiness” segment, which includes tourism and consumer brands, is showing clear signs of recovery.
The positive outlook is supported by strong first-quarter 2026 earnings from Fosun’s core A-share subsidiaries. Fosun Pharmaceutical Co. reported a 21.96 percent increase in adjusted net profit to RMB 871 million on revenue of RMB 10.07 billion. In the consumer and tourism sectors, Yuyuan Inc. saw net profit surge 203 percent to RMB 1.57 billion, while Fosun Tourism Group’s Atlantis Sanya resort posted a 90 percent year-over-year jump in inbound tourists during the May Day holiday.
Fosun’s management outlined plans to accelerate its valuation recovery by optimizing its portfolio and reducing debt. The company aims to lower interest-bearing debt at the group level to below RMB 60 billion by speeding up the sale of heavy assets and non-core subsidiaries. Other investment banks, including Goldman Sachs and UBS, have also published reports seeing a re-rating for the stock as historical burdens are cleared.
The company’s plans to boost shareholder returns further demonstrate management’s confidence. Fosun will implement a share buyback of up to HK$1 billion, while major shareholders and management intend to purchase an additional HK$500 million in stock. The company also committed to a cash dividend of at least RMB 1.5 billion for 2026 and will raise the payout ratio to 35 percent from 20 percent.
This article is for informational purposes only and does not constitute investment advice.
